Veteran investor and operating executive focused on growth-stage healthcare and technology companies. Tracey Daigle combines operational leadership in scaling commercial teams with deal execution experience across growth equity and strategic M&A. Active board member and advisor to startups, she emphasizes revenue acceleration, governance upgrades, and go-to-market transformation to drive liquidity and valuation expansion.
Veteran investor and operating executive focused on growth-stage healthcare and technology companies. Tracey Daigle combines operational leadership in scaling commercial teams with deal execution experience across growth equity and strategic M&A. Active board member and advisor to startups, she emphasizes revenue acceleration, governance upgrades, and go-to-market transformation to drive liquidity and valuation expansion.
Builds concentrated growth-stage portfolios in healthcare and enterprise software, prioritizing companies with defensible products and clear commercialization paths. Capital deployment favors rounds that accelerate revenue and professionalize governance, with dual focus on go-to-market scaling and strategic M&A as exit engines. Investment style blends operational stewardship—placing board members, driving sales leadership hires, and instituting KPI-driven commercialization plans—with selective follow-on support to de-risk milestones. Time horizon is multi-year growth-to-liquidity; risk management emphasizes measurable revenue traction, customer concentration limits, and governance upgrades that increase valuation optionality.
Builds concentrated growth-stage portfolios in healthcare and enterprise software, prioritizing companies with defensible products and clear commercialization paths. Capital deployment favors rounds that accelerate revenue and professionalize governance, with dual focus on go-to-market scaling and strategic M&A as exit engines. Investment style blends operational stewardship—placing board members, driving sales leadership hires, and instituting KPI-driven commercialization plans—with selective follow-on support to de-risk milestones. Time horizon is multi-year growth-to-liquidity; risk management emphasizes measurable revenue traction, customer concentration limits, and governance upgrades that increase valuation optionality.
| Trades 616 | Longs Won 466/616 75% | Profit Factor 40.09 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $402,440.6 |
| Average Win $94,715.75 | Best Trade (Jul 16) $8.71M | Sharpe Ratio -10.41 |
| Average Loss -$7,338.95 | Worst Trade (Jun 30) -$126,477.69 | Z-Score 7.95 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 1w 1d | Expectancy $69,864.77 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 22,222 | 20,000 | 17,778 | 15,556 | 13,333 | 11,111 | 8,889 | 6,667 | 4,444 | 2,222 |